| 甲磺酸伊马替尼临床研究概况 |
| |
| 引用本文： | 郑斌,危晴岚,刘茂柏. 甲磺酸伊马替尼临床研究概况[J]. 海峡药学, 2006, 18(6): 78-80 |
| |
| 作者姓名： | 郑斌 危晴岚 刘茂柏 |
| |
| 作者单位： | 福建医科大学附属协和医院,福州,350001;福建医科大学附属协和医院,福州,350001;福建医科大学附属协和医院,福州,350001 |
| |
| 摘 要： | 甲磺酸伊马替尼是一种蛋白质酪氨酸激酶抑制剂,用于治疗Ph染色体阳性慢性粒细胞白血病和恶性胃肠道间质肿瘤。本文从耐药机制、不良反应、生活质量考察、药物经济学成本-效用分析等方面综述了其最新临床研究进展。
|
| 关 键 词： | 甲磺酸伊马替尼 慢性粒细胞白血病 耐药机制 不良反应 |
| 文章编号： | 1006-3765（2006）06-0078-03 |
The Advances in Clinical Study of Imatinib Mesilate |
| |
| ZHEN-Bin,WEI Qing-lan,LIU Mao-bai. The Advances in Clinical Study of Imatinib Mesilate[J]. Strait Pharmaceutical Journal, 2006, 18(6): 78-80 |
| |
| Authors: | ZHEN-Bin WEI Qing-lan LIU Mao-bai |
| |
| Affiliation: | Union hospital affiliated to Fujian Medical University, Fuzhou 350001, China |
| |
| Abstract: | Imatinib mesilate is a protein-tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and malignant gastrointestinal stromal tumors.In this article we reviewed the advances in clinical study of imatinib including its mechanism of resistance,adverse events,life quality study and cost-effective analysis,etc. |
| |
| Keywords: | Imatinib mesilate Chronic myelogenous leukemia Mechanism of resistance Adverse events |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
